Adam Houldsworth

IAM

Articles

Results 1 to 5 of 65


Breaking: Vaccine IP waiver agreed by WTO members

Global - June 17 2022 A consensus agreement among World Trade Organisation members has been reached to waive certain international IP protection commitments in the field…

CRISPR IP deals continue apace despite legal battles

Global, USA - January 28 2022 The first month of 2022 has seen a slew of CRISPR IP deals, with several large pharmaceutical companies deepening their investments in cutting-edge…

No, IP rights are not the barrier to covid-19 vaccine supplies

Global - February 6 2021 Concerns continue to be raised about the role of patents in the coronavirus pandemic response but, argues IAM life sciences reporter Adam Houldsworth…

Your guide to covid-19 vaccine stakeholders’ IP strategies

USA - November 19 2020 IAM examines the approaches taken by - and the issues facing - the leading companies in the race to find effective coronavirus inoculations With a…

Moderna's covid vaccine is promising news, but IP issues may mean the financial windfall it enjoys are limited

USA - November 16 2020 Senior members of the management team at Moderna have hailed the news that a covid-19 vaccine developed by the company shows 95% efficacy. However…

Joff Wild